11:16 PM EDT, 08/02/2026 (MT Newswires) -- AstraZeneca (AZN.L, AZN.ST) is discussing a potential merger with Bristol Myers Squibb, or BMS, for a combined valuation of $400 billion, London's Financial Times reported Sunday, citing people familiar with the matter. The talks between UK drugmaker AstraZeneca and its US peer have taken place in recent months, according to the report. The people said a potential deal could be announced in the near future while cautioning that it may still be delayed or fall apart. AstraZeneca declined to comment, while BMS did not immediately respond to MT Newswires' request for comment. (Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.